Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After ¹³¹I Treatment

Figures & data

Table 1 Clinical Implications of Response to Therapy Reclassification in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy and Radioiodine Remnant Ablation

Category	Definitions
ER	Negative imaging and either Suppressed Tg < 0.2 ng/mL or Stimulated Tg < 1 ng/mL
IDR	Negative imaging and Suppressed Tg ≥ 1 ng/mL or Stimulated Tg ≥ 10 ng/mL or rising Anti-Tg antibody levels
BIR	Structural or functional evidence of disease with any Tg level with or without Anti-Tg antibodies
SIR	Non-specific findings on imaging studies; faint uptake in thyroid bed on RRA scanning; Non stimulated Tg detectable, but < 1 ng/mL; Stimulated Tg detectable, but < 10 ng/mL or Anti-Tg antibodies stable or declining in the absence of structural or functional disease

Abbreviations: ER, excellent response; IDR, indeterminate response; BIR, biochemical incomplete response; SIR, structural incomplete response.

Figure 1 (A) indicates RX-WBC residual thyroid only; (B) indicates residual thyroid with lymph node metastasis.

Table 2 Comparison of General Data Between ER Group and NER Group

	ER Group (n=139)	NER Group (n=67)	Statistic	P value
Male (case)	37 (26.6%)	22 (32.8.%)	0.855	0.355
Female (case)	102 (73.4%)	45 (67.2%)
Age (case)	43.9±10.6	43.2±10.7	0.461^b	0.645
<55 year (case)	115 (82.7%)	58 (86.6%)	0.494	0.482
≥55 year (case)	24 (17.3%)	9 (13.4)
TT (day)	81.0 (66.0~95.0)	78.5 (61.0~90.7)	−1.224^a	0.221
<90 days (case)	94 (67.6%)	50 (74.6%)	1.053	0.305
≥90 days (case)	45 (32.4%)	17 (25.4%)
Single focal (case)	90 (64.7%)	48 (71.6%)	0.972	0.324
Multi focal (case)	49 (35.3%)	19 (28.4%)
No HT (case)	126 (90.6%)	45 (67.2%)	17.677	<0.001
HT (case)	13 (9.4%)	22 (32.8%)
No extracapsular spread (case)	101 (72.7%)	51 (76.1%)	0.279	0.597
Extracapsular spread (case)	38 (27.3%)	16 (23.9%)
TMD (mm)	10.0 (0.0~10.0)	10.0 (0.0~10.0)	−0.164	0.870
Number of lymph node (case)	2.0 (1.0~4.0)	2.0 (1.0~5.0)	−0.849	0.396
Central zone (number)	2.0 (1.0~3.0)	1.0 (1.0~3.0)	−1.493	0.135
Lateral cervical region (number)	0.0 (0.0~1.0)	2.0 (0.0~3.0)	−3.227	0.001
BRAF^V600E mutant type	106 (76.3%)	57 (85.1%)	2.121	0.145
BRAF^V600E wild type	33 (23.7%)	10 (14.9%)
UIE levels (ug/L)	88.0 (58.0~139.0)	115.0 (64.0~201.0)	−1.987^a	0.047
<100 ug/L (case)	82 (59.0%)	29 (43.3%)	6.345	0.042
100~200 ug/L (case)	39 (28.1%)	21 (31.3%)
>200 ug/L (case)	18 (12.9%)	17 (25.4%)
Ps-Tg levels (ng/mL)	1.0 (0.1~3.0)	4.0 (1.0~11.0)	−4.591^a	<0.001
Ps-TSH levels (mIU/L)	100.0 (77.0~100.0)	100.0 (82.0~100.0)	−0.935^a	0.350
30~60 levels (case)	16 (11.5%)	6 (9.0%)	1.591	0.451
60~90 levels (case)	38 (27.3%)	14 (20.9%)
90~ levels (case)	85 (61.2%)	47 (70.1%)
Residua (case)	79 (56.8%)	36 (53.7%)	0.674	0.756
Remnant with lymph nodes (case)	60 (43.2%)	41 (46.3%)

Notes: measurement data conforming to normal distribution are expressed in $\overline{x}$±s; those not conforming to normal distribution are expressed in M (P25~P75); ^aas Mann Whitney U-test, ^bas independent samples t-test, and the rest as χ² test.

Abbreviations: ER, excellent response; NER, non-excellent response; TT, time from last surgery to first ¹³¹I treatment; HT, Hashimoto’s thyroiditis; TMD, tumor maximum diameter.

Table 3 Multivariate Analysis for Achieving Optimal Treatment (ER) Response

Variable		β	Statistic	OR (95% CI)	P value
Coexisting HT (case)	No	Reference		Reference
	Yes	−1.467	11.550	0.231 (0.099~0.537)	0.001
LLNS (case)		0.075	1.020	1.078 (0.932~1.247)	0.312
UIE levels (ug/L)	100	Reference		Reference
	100~200	−0.137	0.016	0.872 (0.103~7.413)	0.900
	200	−0.147	0.033	0.863 (0.176~4.222)	0.856
Ps-Tg levels (ng/mL)		0.131	14.610	1.140 (1.066~1.220)	<0.001

Abbreviations: HT, Hashimoto’s thyroiditis; LLNS, Lateral cervical region of lymph node numbers.

Figure 2 The nomogram risk model for predicting the short-term outcome of papillary thyroid micro carcinoma after ¹³¹I treatment.

Figure 3 Calibration curve verification of the nomogram model.